Loading data for EW — first visit, this takes a few seconds.
Edwards Lifesciences Corporation
88.25 -1.03 (-1.15%)
88.25 +0.00%
- Market Cap
- $50.87B
- Volume
- 3.88M
- Dividend yield
- n/a
- Next earnings date
- Oct 29, 2026
Edwards Lifesciences Corporation (EW) Stock Price, Analysis & Data
Intrinsic Value
Analyst Forecast
Stock Forecasts →$84.00 – $110.00
Median $101.50 · 15.01% upside
Latest Earnings
| Reported | Vs estimate | YoY Change | |
|---|---|---|---|
| Revenue | — | n/a | n/a |
| EPS | $0.78 | +$0.04 | +16.42% |
Metrics
- Bid
- 88.55
- Market Cap
- 50.9B
- Revenue (ttm)
- 6.51B
- Net Income (ttm)
- 980M
- 0.85
- 1.68
- 52.53
- 26.13
- P/B (ttm)
- 4.79
- P/S (ttm)
- 7.81
- Earnings Date
- Oct 29, 2026
- Ask
- 88.28
- Volume
- 3,880,106
- Avg. Volume (20D)
- 4,105,759
- Open
- 89.21
- Previous Close
- 89.28
- Day's Range
- 88.00 - 89.58
- 52-Week Range
- 72.30 - 96.29
- Analyst
- Buy
- Price Target
- 101.5 (15.01%)
- Dividends
- n/a
- Ex-Dividend Date
- n/a
About Edwards Lifesciences Corporation
View profile →Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Industry Medical Devices
Sector Healthcare
IPO Date Mar 27, 2000
Employees 16,000
Stock Exchange NYSE
Ticker Symbol EW
Website https://www.edwards.com